Ag-Catalyzed Thiocyanofunctionalization of Terminal Alkynes To Access Alkynylthiocyanates and α-Thiocyanoketones
作者:Jie Yang See、Yu Zhao
DOI:10.1021/acs.orglett.8b03162
日期:2018.12.7
Unprecedented one-pot thiocyanofunctionalizations of terminal alkynes to deliver alkynylthiocyanates and alpha-thiocyanoketones using a silver-catalyzed procedure or under silver/gold relay catalysis is reported. These synthetically valuable organothiocyanates are accessed in high efficiency, and their derivatization into a variety of valuable sulfur-containing heterocycles and sulfides has also been demonstrated.
NBS or DEAD as effective reagents in α-thiocyanation of enolizable ketones with ammonium thiocyanate
Ketones possessing a-hydrogen undergo smooth thiocyanation with ammonium thiocyanate in the presence of N-bromosuccinimide (NBS) at room temperature in acetonitrile under neutral conditions to produce the corresponding alpha-ketothiocyanates in excellent yields with high selectivity. The use of NBS makes this procedure simple, convenient and cost effective. In addition, diethyl azodicarboxylate (DEAD) was also found to promote this reaction under mild conditions. (c) 2011 Elsevier Ltd. All rights reserved.
Thiopegan Derivatives. XXIII. Synthesis of 5H-Thiazolo[3,2-a]quinazolin-5-one and 5H-Thiazolo[2,3-b]quinazolin-5-one Derivatives Containing Phenolic, Alkoxy, and Alkyl Groups
作者:K. S. Dhami、S. S. Arora、K. S. Narang
DOI:10.1021/jm00340a027
日期:1963.7
INTERFERON-INDUCING COMPOUNDS AND USES THEREOF
申请人:Shaw Megan
公开号:US20120308608A1
公开(公告)日:2012-12-06
Provided herein are Compounds that induce interferon production and methods for identifying such Compounds. Also provided herein are compositions comprising such Compounds and methods of using such Compounds to treat interferon-sensitive diseases such as viral infections, cancer, and multiple sclerosis.
COMPOSITIONS OF ALDH1A1 INHIBITORS AND METHODS OF USE IN TREATING CANCER
申请人:Indiana University Research & Technology Corporation
公开号:US20150306108A1
公开(公告)日:2015-10-29
The present invention provides inhibitors of ALDH1A1 activity which have substantially no effect on either ALDH2 or ALDH3A1. Compositions and methods of use, as well as methods to treat cancer using the ALDH1A1 inhibitors, are also provided.